<DOC>
	<DOCNO>NCT01704781</DOCNO>
	<brief_summary>During course HIV infection number CD4 cell decrease , result reduced immunological response ultimately immune deficiency . Vacc-4x peptide-based HIV immunotherapy primary objective strengthen immune system 's response HIV p24 . By add Lenalidomide , immunomodulatory agent , support drug , anticipated effect Vacc-4x might enhance .</brief_summary>
	<brief_title>Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo HIV-1-infected Subjects Antiretroviral Therapy ( ART )</brief_title>
	<detailed_description>Human immunodeficiency virus ( HIV ) infect CD4 subset T-cells critical initiating immune response infection . The level CD4 cell blood marker patient 's immunological status . The number CD4 cell decrease course HIV infection result reduce immunological response eventually immune deficiency . Vacc-4x one peptide-based therapeutic vaccine test , consist four , slightly modify HIV Gag p24 consensus peptide . Vacc-4x first test intradermal injection use GM-CSF adjuvant . A recent multinational placebo-controlled study find improvement vaccine-specific T cell immunity decrease viral load ( presented AIDS vaccine 2011 conference , Bangkok ) . Lenalidomide ( CC-5013 ) substance class immunomodulatory agent . The lenalidomide mechanism action include anti-neoplastic , pro-erythropoietic , immunomodulatory property . Lenalidomide inhibit proliferation certain hematopoietic tumor cell , enhances T cell- Natural Killer ( NK ) cell-mediated immunity increase number NK T cell . The anti-HIV p24 immune response result Vacc-4x immunization could combination ART potentially improve immune reconstitution patient fully regain healthy CD4 level ( &gt; 600 x106/L ) . Adding immunomodulatory agent Lenalidomide ( CC-5013 ) Vacc-4x immunization could enhance immune response Vacc-4x strengthen immune reconstitution .</detailed_description>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Men , age ≥ 18 ≤ 55 year time screen . 2 . Women , age ≥ 50 ≤ 55 year time screening , childbearing potential ( see Exclusion criterion , point 9 ) . Childbearing status must document . 3 . Clinically stable ART last 18 month ( change therapy allow long viral load stable ) . 4 . Well control treatment failure due ART resistance past 5 . Screening plasma viral load ( HIV1 RNA ) less 50 copies/mL last six month . If screen value 50500 copies/mL rescreening allow . Single blip ( 500 copies/mL ) allow . 6 . Screening CD4 cell count ≥ 200x10^6 cells/L ≤500x10^6 cells/L . ( Rescreening allow ) 7 . Laboratory test result within range : Absolute neutrophil count ( ANC ) &gt; 1.0x10^9 /L , Platelet count &gt; 75x10^9 /L eGRF ( MDRD ) &gt; 60 mL/min 8 . Signed informed consent 9 . Willingness adhere Global Pregnancy Prevention Risk Management Plan Lenalidomide 1 . Reported prestudy AIDSdefining illness within previous year 2 . Malignant disease . 3 . On chronic treatment immunosuppressive therapy . 4 . Autoimmune disorder , present past increase risk disease exacerbation . 5 . Unacceptable value hematologic clinical chemistry parameter ( include associate hemophilia ) , judge Investigator Sponsor ( designee ) , include creatinine value &gt; 1.5x upper limit normal ( ULN ) , AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase value &gt; 2.5x ULN . 6 . Concurrent chronic active infection viral hepatitis B C tuberculosis . 7 . Previous thromboembolic event patient currently immobilize 8 . Sexually active subject adhere Global Pregnancy Prevention Risk Management Plan Lenalidomide 9 . Current participation clinical therapeutic study . 10 . Females childbearing potential exclude trial . A female childbearing potential ( FCBP ) sexually mature female : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( i.e . menses time precede 24 consecutive month ) . 11 . The development erythema nodosum characterize desquamate rash previously 12 . Incapability compliance treatment protocol , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>CD4</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Dose escalation assessment lenalidomide</keyword>
	<keyword>Human immunodeficiency virus-1 ( HIV-1 )</keyword>
	<keyword>HIV</keyword>
	<keyword>Immunomodulatory</keyword>
	<keyword>Infection</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Vacc-4x</keyword>
</DOC>